Sanofi (NASDAQ:SNY) is one of the Best and Cheap Stocks to Buy Right Now. On September 24, Sanofi (NASDAQ:SNY) announced an additional $625 million investment in Sanofi Ventures to boost the fund’s total assets to over $1.4 billion. Management noted that this investment supports the venture’s long-term focus on biotech and digital health startups. Sanofi (NASDAQ:SNY) founded Sanofi Ventures in 2012; which has invested more than $800 million in around 70 companies internationally. The venture invests in co ...

Pfizer Inc. (NYSE:PFE) is one of the Best and Cheap Stocks to Buy Right Now. On September 30, Reuters reported that Pfizer Inc. (NYSE:PFE) and President Donald Trump had announced a deal to lower Medicaid drug prices in the US. The company agreed to match its Medicaid prices to those it charges in other developed countries in exchange for tariff relief on its imports. President Trump noted that Pfizer Inc. (NYSE:PFE) will offer its most favoured nation prices on all new drugs launched in the United States ...

Group 1: Tariffs on Entertainment and Lumber - President Trump announced a 100% tariff on foreign-made films to encourage domestic production, but the market reaction was muted, with analysts not viewing it as a serious threat [2][3] - The U.S. stock market remained stable despite the tariff announcement, while Indian media stocks declined by 5% and Netflix shares fell by 1.5% [3] - New tariffs of 10% on imported lumber and 25% on kitchen cabinets and other furniture were set to take effect on October 14, 2025, citing national security concerns [4][5] - Companies like MasterBrand saw a 6% increase in shares due to domestic manufacturing advantages, while high-end retailers faced challenges from increased import taxes [5] Group 2: Pharmaceutical Sector Developments - A significant drug pricing deal was announced between President Trump and Pfizer, where Pfizer would cut drug prices and invest $70 billion in U.S. manufacturing [6] - Pfizer's stock surged by 6.83% to $25.48, with trading volume reaching over 153 million shares, indicating strong market confidence [7][8] - The S&P 500 Pharmaceuticals Index rose nearly 4%, with other major drugmakers also experiencing gains, although some experts questioned the long-term savings for consumers [8] Group 3: Market Resilience Amidst Uncertainty - Despite the looming threat of a U.S. government shutdown, major U.S. indices showed resilience, with the Dow Jones closing at a record high of 46,397.89 [9][10] - Analysts noted that investors appeared to have priced in the potential impact of a shutdown, although concerns about new tariffs renewing business uncertainty remained [10] - Global trade dynamics continued to evolve, with mixed reactions to Trump's tariffs, as some regions adapted better than expected [11] Group 4: Overall Market Impact - The recent policy announcements from President Trump have created a complex environment for investors, with mixed impacts across different sectors [12] - The broader market has shown surprising resilience, continuing its upward trajectory despite political uncertainties [12][13] - Investors are left to navigate the contradictions and potential impacts of these announcements as they prepare for future developments [13]

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Biopharmaceutical giant Amgen said it plans to invest $650 million to increase drug production at its Juncos, Puerto Rico, facility, as part of a larger effort to expand its U.S. manufacturing network. The investment is expected to create nearly 750 jobs, including in construction and highly-skilled manufacturing roles. It also will support advanced techn ...

The pharmaceutical industry’s US lobbying organization announced a new website on Monday to connect patients with companies selling discounted medicines online https://t.co/GH7Rr3W36L ...

Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives and delivering growth through innovative medicines and vaccines [2] - The company leverages its understanding of the immune system to create treatments that benefit millions globally, with a commitment to addressing urgent healthcare, environmental, and societal challenges [2] Financial Information - Sanofi's Q3 2025 Aide mémoire is now available on the company's website, which assists in financial modeling of quarterly results [1] - The document includes details on non-comparable items, foreign currency impact, and share count [1] - Sanofi's second quarter 2025 results are scheduled for publication on October 24, 2025 [1] Stock Information - Sanofi is listed on EURONEXT under the ticker SAN and on NASDAQ under the ticker SNY [3]

Merck & Co., Inc. (NYSE: MRK ) is a global healthcare powerhouse that develops and markets vaccines, biologic therapies, and other medicines to treat both humans and animals. The company is most known for its blockbuster drugs — theDear Reader,I am a Senior Derivatives Expert with over 10 years of experience in the field of Asset Management, specializing in equity analysis and research, macroeconomics, and risk-managed portfolio construction. My professional background covers both institutional and private ...

Medicines & Healthcare System - Medicines play a crucial role in people's lives, with prescribing being the most common healthcare intervention [2][3] - The UK spends approximately 25 billion pounds annually on medicines, the largest expense for the National Health Service after staff costs [3] - Over 1 million people in the UK take 10 or more medicines daily, increasing the risk of side effects, drug interactions, and hospitalization [8][9] - Up to 50% of medicines are not taken as intended, leading to 300 million pounds worth of wasted medicines in the UK [10] - Medicines are implicated in 165% of unplanned hospital admissions in the UK as a primary or contributing cause [13] - Deprescribing, stopping or reducing medication dosages, can significantly improve patient outcomes [16][17][18][19] - Shared decision-making, involving patients in treatment choices, is crucial, utilizing the "BRAN" framework (Benefits, Risks, Alternatives, and what if we do Nothing) [20][21] Environmental Impact of Medicines - Medicines cause ecological damage, exemplified by the 95% decline in India's vulture population due to diclofenac [23] - Pharmaceutical pollution is present in rivers worldwide, including English national parks, with active ingredients like antibiotics, antidepressants, and hormones detected [26][27] - Pharmaceutical pollution impacts wildlife, causing mortality, behavioral changes, and reproductive issues, such as feminization of fish from oral contraceptives [28] - The pharmaceutical industry needs to design greener drugs, and the water industry should improve wastewater processes [29][30]

Core Viewpoint - Roche is proposing a modernization of its capital structure, which includes the exchange of existing non-voting equity securities for participation certificates, subject to shareholder approval at the 2026 Annual General Meeting [1][3][9]. Group 1: Capital Structure Changes - The Board of Directors will propose to shareholders the exchange of non-voting equity securities ("Genussscheine") for participation certificates with a nominal value of CHF 0.001 each [1][3]. - To ensure equal treatment, the nominal value of bearer shares will be reduced from CHF 1.00 to CHF 0.001, with a cash repayment of CHF 0.999 per bearer share, totaling CHF 106,584,309 [2][9]. - The participation certificates will be listed on the SIX Swiss Exchange and will have the same dividend entitlement and liquidation proceeds as bearer shares [3][9]. Group 2: Discontinuation of Printed Materials - Roche will cease issuing printed dividend vouchers after the payment of the dividend for the financial year 2025 and the completion of the capital structure changes [4][6]. - Home custodians are encouraged to submit printed certificates and dividend vouchers to a depository bank for conversion into intermediated securities to ensure smooth future dividend payments [5][6]. Group 3: Future Practices - The transition to intermediated securities aligns with modern market practices, and Roche will no longer issue printed certificates for any equity securities in the future [6][9].

Core Viewpoint - Roche is proposing a modernization of its capital structure, which includes the exchange of existing non-voting equity securities for participation certificates, to be approved at the Annual General Meeting on March 10, 2026 [1][3]. Group 1: Capital Structure Changes - The proposal includes reducing the nominal value of bearer shares from CHF 1.00 to CHF 0.001, with a cash repayment of CHF 0.999 per bearer share, totaling CHF 106,584,309 [2][9]. - The exchange of Genussscheine for participation certificates is in line with Roche's articles of incorporation and is driven by revised Swiss corporate law, ensuring that participation certificates will have the same economic rights as bearer shares [3][9]. Group 2: Dividend and Securities Management - After the dividend payment for the financial year 2025 and the capital structure changes, Roche will discontinue the issuance of printed dividend vouchers [4][6]. - Home custodians are encouraged to submit their printed certificates and dividend vouchers to a depository bank for conversion into intermediated securities to facilitate future dividend payments [5][6]. Group 3: Future Outlook - The participation certificates will be listed on the SIX Swiss Exchange and will maintain the same dividend entitlement and liquidation proceeds as bearer shares [3][9]. - Detailed explanations of the proposals will be provided to shareholders ahead of the 2026 AGM [3].